Related Experiment Video
Updated: May 12, 2026

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
Androgen receptor: past, present and future
Lucy J Schmidt1, Donald J Tindall
1Department of Urology Research, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
Androgens and the androgen receptor have been the focus of prostate cancer research since the early 1940s, when Huggins and Hodges demonstrated that removal of androgens caused advanced prostate cancer to regress. Since that time, a large number of androgen deprivation therapies have been developed in an effort to cure this disease, but prostate cancer remains one of the leading causes of cancer death in males worldwide. This is due in part to the emergence of castration- recurrent prostate cancer in patients with advanced disease who have failed androgen deprivation therapy. The androgen receptor is still a major player in castration-recurrent disease, and though much has been discovered since the early work of Huggins and Hodges regarding how prostate cancer cells manage to avoid the effects of androgen deprivation, survival times for men with advanced prostate cancer have changed only modestly. Research is now directed toward delineating the mechanisms of action of the androgen receptor under castrate conditions, whether through amplification of the AR, mutation, expression of splice variants, use of alternate signaling pathways, aberrant expression and activation of coregulators, or intratumoral androgen biosynthesis. Genome-wide association studies are also adding to the wealth of knowledge surrounding the androgen receptor, and with this knowledge comes the ability to design new drug therapies directed toward eradication of this disease.
Insights
Prostate cancer research focuses on androgens and the androgen receptor (AR). Despite therapies, castration-recurrent prostate cancer persists, driving research into AR mechanisms for new drug development.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- Prostate cancer remains a leading cause of cancer death in men globally.
- Androgen deprivation therapy (ADT) is a primary treatment, but castration-recurrent prostate cancer (CRPC) emerges.
- The androgen receptor (AR) remains central to CRPC, despite decades of research.
Purpose of the Study:
- To review the persistent role of the androgen receptor (AR) in advanced prostate cancer, particularly in castration-recurrent disease.
- To explore the mechanisms by which prostate cancer cells evade ADT.
- To highlight current research directions and the potential for novel therapeutic strategies targeting the AR.
Main Methods:
- Review of historical and current research on androgens and the androgen receptor in prostate cancer.
- Analysis of mechanisms driving castration-recurrent prostate cancer (CRPC).
- Incorporation of findings from genome-wide association studies (GWAS).
Main Results:
- Prostate cancer remains a significant cause of male mortality despite extensive research and ADT development.
- CRPC develops in patients who fail ADT, with the AR playing a critical role.
- Mechanisms of AR reactivation include amplification, mutation, splice variants, alternative pathways, coregulator activity, and intratumoral androgen synthesis.
Conclusions:
- Understanding AR function under castrate conditions is crucial for overcoming treatment resistance.
- Emerging knowledge from GWAS and mechanistic studies offers new avenues for drug development.
- Targeting the AR and its associated pathways holds promise for eradicating advanced prostate cancer.
Related Concept Videos
Intracellular Hormone Receptors
Testosterone: Functions and Regulation
Signal Transduction: Overview
Typically, signal transduction involves three...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Internal Receptors
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
